MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

REVOLUTION Medicines Inc

Gesloten

SectorGezondheidszorg

47.86 3.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

45.97

Max

49.41

Belangrijke statistieken

By Trading Economics

Inkomsten

-34M

-248M

Winstmarge

-74.379

Werknemers

700

EBITDA

-24M

-261M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+52.9% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.8B

8.7B

Vorige openingsprijs

44.76

Vorige sluitingsprijs

47.86

Nieuwssentiment

By Acuity

50%

50%

191 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 okt 2025, 20:45 UTC

Winsten

Costco Wholesale Sales Climb in September, Early October

8 okt 2025, 20:12 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 okt 2025, 16:39 UTC

Belangrijke Marktbewegers

Mining Shares Rise as Gold Prices Soar

8 okt 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 okt 2025, 23:43 UTC

Marktinformatie

Gold Falls on Possible Profit-Taking -- Market Talk

8 okt 2025, 23:18 UTC

Acquisities, Fusies, Overnames

JD Logistics to Finance Acquisition Using Internal Funds

8 okt 2025, 23:17 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 okt 2025, 23:16 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 okt 2025, 21:54 UTC

Marktinformatie
Winsten

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 okt 2025, 21:30 UTC

Marktinformatie

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 okt 2025, 21:26 UTC

Marktinformatie
Winsten

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 19:15 UTC

Marktinformatie

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 okt 2025, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 okt 2025, 18:47 UTC

Marktinformatie

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Will Remain a Publicly Traded Co >TASK

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 okt 2025, 18:07 UTC

Marktinformatie

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 okt 2025, 15:57 UTC

Marktinformatie

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 okt 2025, 15:56 UTC

Marktinformatie

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 okt 2025, 15:53 UTC

Marktinformatie

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 okt 2025, 15:43 UTC

Acquisities, Fusies, Overnames

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 okt 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

52.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.22 USD  52.9%

Hoogste 80 USD

Laagste 37.91 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

191 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat